Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
244.38B | 195.19B | 180.03B | 174.27B | 160.55B | Gross Profit |
244.38B | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
5.27B | 8.54B | 8.45B | 7.94B | 8.15B | EBITDA |
9.48B | 9.57B | 12.91B | 10.41B | 14.48B | Net Income Common Stockholders |
3.43B | 5.16B | 6.70B | 5.37B | 8.46B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
7.55B | 8.75B | 6.83B | 6.00B | 11.51B | Total Assets |
155.88B | 152.76B | 143.93B | 154.89B | 155.45B | Total Debt |
31.97B | 30.93B | 31.09B | 33.67B | 32.92B | Net Debt |
24.42B | 23.11B | 25.17B | 28.59B | 22.74B | Total Liabilities |
114.64B | 106.41B | 98.98B | 107.70B | 105.06B | Stockholders Equity |
41.03B | 46.22B | 44.87B | 47.11B | 50.32B |
Cash Flow | Free Cash Flow | |||
8.96B | 10.24B | 7.36B | 6.04B | 9.26B | Operating Cash Flow |
10.36B | 11.81B | 8.66B | 7.19B | 10.35B | Investing Cash Flow |
-2.10B | -5.17B | 3.10B | -3.61B | 2.98B | Financing Cash Flow |
-7.65B | -4.29B | -11.24B | -8.21B | -8.53B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $87.10B | 31.55 | 51.23% | 0.40% | 14.29% | -1.20% | |
76 Outperform | $87.75B | 19.01 | 6.07% | 4.07% | 4.02% | -43.51% | |
74 Outperform | $31.68B | 10.22 | 12.59% | ― | 8.85% | 33.30% | |
73 Outperform | $89.52B | 27.23 | 7.87% | 1.70% | 25.21% | -29.37% | |
69 Neutral | $35.61B | 29.55 | 7.40% | 1.34% | 10.70% | -49.85% | |
69 Neutral | $548.34B | 38.66 | 15.88% | 2.01% | 8.68% | ― | |
51 Neutral | $5.32B | 3.39 | -40.26% | 2.89% | 17.93% | 2.48% |
On March 13, 2025, Cigna announced the termination of Eric P. Palmer, Executive Vice President for Enterprise Strategy and CEO of Evernorth Health Services, effective April 26, 2025. The agreement includes a severance package with cash payments and continued vesting of certain equity awards, reflecting the company’s strategic management decisions and impacting its leadership structure.
Spark’s Take on CI Stock
According to Spark, TipRanks’ AI Analyst, CI is a Outperform.
Cigna’s overall stock score is driven by strong financial performance and positive earnings call, despite pressures from medical costs in the stop loss segment. Technical indicators show a positive short-term trend, but valuation remains a concern due to a relatively high P/E ratio. Corporate events further bolster confidence in future growth.
To see Spark’s full report on CI stock, click here.
On March 13, 2025, Cigna announced leadership changes effective March 31, 2025, with Brian C. Evanko becoming President and COO, and Ann M. Dennison stepping in as CFO. These changes come with new compensation arrangements reflecting their roles. Additionally, the company reaffirmed its projected 2025 financial outlook, including consolidated adjusted income from operations of at least $29.50 per share and significant pre-tax income from its Evernorth and Cigna Healthcare segments.
The Cigna Group announced its intention to reaffirm its projected full-year 2025 consolidated adjusted income from operations of at least $29.50 per share during upcoming meetings with investors and analysts. This reaffirmation highlights the company’s confidence in its financial performance and strategic initiatives, despite the challenges and uncertainties in the healthcare sector.